Coronaviridae

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Retrieved on: 
Tuesday, July 13, 2021
Coronaviridae, Variants of SARS-CoV-2, COVID-19, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Zeta variant

Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.

Key Points: 
  • Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.
  • In a single reaction, the variants diagnostic kit identifies a total of six COVID-19 variants that are known to be originated from India such as Delta, Delta Plus, and Kappa, and Gamma(Brazil), Beta(South Africa), and Epsilon(California).
  • Seegene also said that it has successfully developed a research-use-only diagnostic tests, 'Allplex SARS-CoV-2/P681R Assay,' to precisely target the Delta and Delta Plus variants.
  • According to Seegene, the combination use of its two assays including 'Allplex SARS-CoV-2 Variants II Assay' and the 'Allplex SARS-CoV-2 Variants I Assay' can screen almost all existing COVID-19 variants.

ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose

Retrieved on: 
Tuesday, July 13, 2021
Coronaviridae, Respiratory diseases, Zoonoses, Sarbecovirus, Atypical pneumonias, Bat virome, COVID-19, Occupational safety and health, TLR2, Severe acute respiratory syndrome, COVID-19 vaccine

By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.

Key Points: 
  • By stimulating innate immune response, we hope to create an additional line of defense against COVID-19 and other respiratory viral infections.
  • The Phase I study is a randomized, double-blind and placebo-controlled, single and multiple ascending dose study.
  • The easy-to-use nasal spray could be helpful in protecting at-risk populations, such as the elderly or patients with chronic respiratory diseases.
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

nference and Mayo Clinic Study Confirms Link Between Anemia and Rehospitalization After COVID-19 Infection Clearance

Retrieved on: 
Monday, July 12, 2021
Coronaviridae, Sarbecovirus, Zoonoses, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome, deCODE genetics

Authors of the study, " Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance ," found that pre-COVID-19 anemia is the strongest clinical signature of long-term COVID-19 phenotypes, and can appear weeks or months after a COVID-19 infection has been cleared from a patient's immune system.

Key Points: 
  • Authors of the study, " Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance ," found that pre-COVID-19 anemia is the strongest clinical signature of long-term COVID-19 phenotypes, and can appear weeks or months after a COVID-19 infection has been cleared from a patient's immune system.
  • By analyzing lab test results for patients rehospitalized after a COVID-19 infection, nference and Mayo Clinic researchers found that patients rehospitalized as a result of long-term COVID-19 symptoms are more likely to have experienced anemia before their diagnosis and during the time they were infected with COVID-19.
  • "This is an excellent demonstration of how nference triangulates various data sets to decode the natural history of diseases," said Venky Soundararajan, PhD, co-founder and chief scientific officer of nference.
  • Through its powerful augmented intelligence software nferX, nference is transforming health care by making biomedical knowledge computable.

Eurofins Viracor Invests in Innovation with the Launch of Coronavirus (COVID-19) SARS-CoV-2 inSIGHT™ T Cell Immunity Testing

Retrieved on: 
Thursday, July 8, 2021
Coronaviridae, Medical specialties, Medicine, Eurofins Scientific, COVID-19 testing, COVID-19, Coronavir, Severe acute respiratory syndrome coronavirus

LEE'S SUMMIT, Mo., July 8, 2021 /PRNewswire/ --As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to innovate with the launch of Coronavirus SARS-CoV-2 inSIGHT T Cell Immunity testing.

Key Points: 
  • LEE'S SUMMIT, Mo., July 8, 2021 /PRNewswire/ --As one of the first commercial labs to deliver COVID-19 testing, Eurofins Viracor, Inc. continues to innovate with the launch of Coronavirus SARS-CoV-2 inSIGHT T Cell Immunity testing.
  • Viracor's inSIGHT T Cell Immunity test delivers an understanding of a patient's response to viral antigens providing critical insight to aid in treatment decisions.
  • SARS-CoV-2 inSIGHT testing joins a robust menu of COVID-19 testing, including the recently-launched cPASS Coronavirus SARS-CoV-2 Neutralizing Antibody test.
  • Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services.

Therma Bright's AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Successfully Detects the COVID-19 Delta Variant Strain

Retrieved on: 
Thursday, July 8, 2021
Coronaviridae, Variants of SARS-CoV-2, Zoonoses, COVID-19, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Delta variant, Severe acute respiratory syndrome coronavirus 2

Toronto, Ontario--(Newsfile Corp. - July 8, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the completion and validation that its AcuVid COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, fast moving COVID-19 Delta B.1.617.2 variant.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - July 8, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the completion and validation that its AcuVid COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, fast moving COVID-19 Delta B.1.617.2 variant.
  • The Delta variant is becoming the fastest moving, most dominant COVID-19 strain globally; on June 24th Therma Bright and its partners announced and initiated the Delta variant study.
  • The study focused on ensuring the Company's AcuVid COVID-19 Rapid Antigen Saliva Test would successfully perform and easily detect the ever-growing list of mutations from the original Wuhan SARS-CoV-2 Novel Coronavirus.
  • Sources: Delta variant news coverage as becoming the dominant COVID-19 variant in US, UK, Europe, India and Africa

SaNOtize’s Anti-Viral Treatment Made Available in Israeli Pharmacies

Retrieved on: 
Thursday, July 8, 2021
Medical devices, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Coronaviridae, Sarbecovirus, Health, Medicine, Bat virome, Severe acute respiratory syndrome, Virus

Enovid was granted an emergency use authorization as a medical device by Israels Ministry of Health earlier this year.

Key Points: 
  • Enovid was granted an emergency use authorization as a medical device by Israels Ministry of Health earlier this year.
  • Enovid releases a small dose of nitric oxide (NO), a natural nanomolecule with proven anti-microbial properties including against SARS-CoV-2, the virus that causes COVID-19.
  • SaNOtize is also pleased to announce the appointments of Dan Suesskind and Elaine Campbell to its Board of Directors.
  • The company has developed and patented a Nitric Oxide Releasing Solution platform technology (NORSTM) to treat and prevent microbial infections.

Inventive Health: COVID-19 Detected in 20 Seconds by Ultra-rapid Mouthwash or Nasal Swab Test Using Spectral Analysis Under MHRA Approval

Retrieved on: 
Thursday, July 8, 2021
Coronaviridae, Health sciences, Sarbecovirus, COVID-19, Occupational safety and health, Public health, Zoonoses, Nasopharyngeal swab, Mouthwash, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Swab

These signatures are interpreted using artificial intelligence as either positive or negative for SAR-Cov-2, the virus that causes COVID-19.

Key Points: 
  • These signatures are interpreted using artificial intelligence as either positive or negative for SAR-Cov-2, the virus that causes COVID-19.
  • Samples can be collected using either a nasopharyngeal swab or non-invasive mouthwash solution.
  • The MHRA approval process is being driven by Inventive Health and is currently focused on the nasopharyngeal swab with the mouthwash alternative following soon.
  • All pathogens such as SARS-CoV-2 have a unique high resolution digital signature that can be detected using spectral analysis.

Study reveals children and youth had highest rates of SARS-CoV-2 infection in Canada before third wave

Retrieved on: 
Wednesday, July 7, 2021
Coronaviridae, Sarbecovirus, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Seroprevalence, COVID-19

This brings the total percentage of Canadians with some form of immunity before the third wave to 3.6%.

Key Points: 
  • This brings the total percentage of Canadians with some form of immunity before the third wave to 3.6%.
  • Younger age groups and especially children and adolescents - had higher rates of antibodies in their blood suggesting a past SARS-CoV-2 infection.
  • The overall seroprevalence of SARS-CoV-2 antibodies was 3.4% among children and youth 1 to 19 years of age between November and April 2021, explains Mr. Gravel.
  • As vaccines had not yet been distributed to this age group at the time of the survey, nearly all of these children and youth had antibodies due to a previous infection.

Verge Genomics Presents Preclinical Data Supporting Broad-Spectrum Potential of Its Novel, Oral Antiviral at the 31st European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
Wednesday, July 7, 2021
Health, Infectious diseases, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Coronaviridae, Sarbecovirus, Antiviral drug, Severe acute respiratory syndrome, COVID-19 drug repurposing research, GC376, the Preclinical Study, PIKfyve, Verge Genomics, THE PRECLINICAL STUDY, PIKFYVE, VERGE GENOMICS

The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.

Key Points: 
  • The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.
  • There remains an urgent need for oral antiviral treatments for SARS-CoV-2 and its variants, said Alice Zhang, CEO and Co-Founder of Verge Genomics.
  • Verge has demonstrated potent antiviral activity in vitro and improvement of SARS-CoV-2-induced pathology in vivo by the PIKfyve inhibitor, VRG101.
  • Verge is focused on developing therapeutics for serious genetic diseases using human genomics and machine learning.

Psomagen Inc. Expands Its COVID-19 Diagnostic Services to Include At-Home Saliva Collection Kits

Retrieved on: 
Wednesday, July 7, 2021
MEN, General Health, Family, Specialty, Consumer, Infectious diseases, Genetics, Retail, Biotechnology, Women, Medical Supplies, Seniors, Health, Medicine, Coronaviridae, Infectious diseases, COVID-19 testing, COVID-19, Medical tests, Curative, DiaSorin, MEN, General Health, Family, Specialty, Consumer, Infectious diseases, Genetics, Retail, Biotechnology, Women, Medical Supplies, Seniors, Health, Medicine, Coronaviridae, Infectious diseases, COVID-19 testing, COVID-19, Medical tests, Curative, DiaSorin

Psomagen, Inc ., a CLIA-certified genetic analysis service provider, is adapting to the publics changing COVID-19 testing needs by expanding its SARS-CoV-2 diagnostic services.

Key Points: 
  • Psomagen, Inc ., a CLIA-certified genetic analysis service provider, is adapting to the publics changing COVID-19 testing needs by expanding its SARS-CoV-2 diagnostic services.
  • In addition to its GutBiome and Gene Trait testing, the company now offers direct-to-consumer saliva collection kits for diagnosing COVID-19 for adults age 18 and older.
  • Psomagen offers two other EUA-authorized SARS-CoV-2 tests including the saliva-based SalivaDirect diagnostic test and the swab-based Psoma COVID-19 RT Coronavirus Test .
  • Psomagen, Inc. , formerly Macrogen USA, delivers genetic sequencing services to the clinical, academic, and consumer markets.